The results revealed that 3 immune stimulators including ICOS (Figure 5A), TNFSF14 (Figure 5B), and ULBP1 (Figure 5C) were negatively correlated with the clinical outcome of patients with GBM, while no significant differences were found in the clinical outcome between low and high expression of immune inhibitors. Here, TNFSF14 is linked to glioblastoma.